beta

ABLX

Ablynx NV

Ablx

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Ablynx NV is a clinical-stage biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.

Market Cap: 3.36 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.ablynx.com

Shares Outstanding: 75.1 Million

Float: 75.1 Million

Dividend: 0.0 (0.0%)

Beta: 14.372817

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 709 Thousand

Ethical Flags

Animal testing

Longest drawdown: 125 trading days

From: 2018-04-18 To: 2018-06-12

Lowest Point:

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

How Do Listed Companies Perform With A U.S. IPO?

via: SeekingAlpha at 2018-04-19 23:18:35:000

US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Wall Street Breakfast: Tax Day At The Supreme Court

via: SeekingAlpha at 2018-04-17 06:59:02:000

A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored … read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%

via: SeekingAlpha at 2018-04-10 06:22:34:000

Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout… The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s... read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Sanofi to commence previous tender offers to acquire Ablynx on April 4

via: SeekingAlpha at 2018-03-29 07:17:27:000

Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX )outstanding shares for45.00 per share/ADS, warrants at 18.66 -41.79 per warrant and convertible bonds at393,700.78 on April 4. More n… read more...

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

via: SeekingAlpha at 2018-02-19 08:00:00:000

Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, … read more...

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

via: SeekingAlpha at 2018-02-19 08:00:00:000

Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, … read more...

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

via: SeekingAlpha at 2018-02-19 08:00:00:000

Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, … read more...

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

via: SeekingAlpha at 2018-02-19 08:00:00:000

Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, … read more...

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

via: SeekingAlpha at 2018-02-19 08:00:00:000

Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, … read more...

Sanofi licenses two additional Nanobody candidates from Ablynx

via: SeekingAlpha at 2018-02-16 09:05:55:000

Ablynx (NASDAQ: ABLX ) announces that Sanofi (NYSE: SNY ) has exercised its option to license two additional target combinations under their July 2017 collaboration aimed at developing and commercializing Nanobody-based therapeutics for immune-mediated inflammatory disorders. More news o… read more...

Sanofi licenses two additional Nanobody candidates from Ablynx

via: SeekingAlpha at 2018-02-16 09:05:55:000

Ablynx (NASDAQ: ABLX ) announces that Sanofi (NYSE: SNY ) has exercised its option to license two additional target combinations under their July 2017 collaboration aimed at developing and commercializing Nanobody-based therapeutics for immune-mediated inflammatory disorders. More news o… read more...

Sanofi licenses two additional Nanobody candidates from Ablynx

via: SeekingAlpha at 2018-02-16 09:05:55:000

Ablynx (NASDAQ: ABLX ) announces that Sanofi (NYSE: SNY ) has exercised its option to license two additional target combinations under their July 2017 collaboration aimed at developing and commercializing Nanobody-based therapeutics for immune-mediated inflammatory disorders. More news o… read more...

Sanofi licenses two additional Nanobody candidates from Ablynx

via: SeekingAlpha at 2018-02-16 09:05:55:000

Ablynx (NASDAQ: ABLX ) announces that Sanofi (NYSE: SNY ) has exercised its option to license two additional target combinations under their July 2017 collaboration aimed at developing and commercializing Nanobody-based therapeutics for immune-mediated inflammatory disorders. More news o… read more...

Sanofi licenses two additional Nanobody candidates from Ablynx

via: SeekingAlpha at 2018-02-16 09:05:55:000

Ablynx (NASDAQ: ABLX ) announces that Sanofi (NYSE: SNY ) has exercised its option to license two additional target combinations under their July 2017 collaboration aimed at developing and commercializing Nanobody-based therapeutics for immune-mediated inflammatory disorders. More news o… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

BioSci Rounds Report For Feb. 1, 2018

via: SeekingAlpha at 2018-02-02 04:26:56:000

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

via: SeekingAlpha at 2018-01-30 03:59:14:000

Market and sector outlook Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

via: SeekingAlpha at 2018-01-30 03:59:14:000

Market and sector outlook Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

via: SeekingAlpha at 2018-01-30 03:59:14:000

Market and sector outlook Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

via: SeekingAlpha at 2018-01-30 03:59:14:000

Market and sector outlook Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

via: SeekingAlpha at 2018-01-30 03:59:14:000

Market and sector outlook Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

via: SeekingAlpha at 2018-01-30 03:59:14:000

Market and sector outlook Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Wall Street Breakfast: Investors Prepare For Earnings Tsunami

via: SeekingAlpha at 2018-01-29 05:48:23:000

While stock index futures are down slightly to start the week, the market could continue its record-setting run with the S&P 500 already on track for a 7.2% gain in January. More than a fifth of the S&P 500 companies will release earnings this week, ranging from tech's he… read more...

Wall Street Breakfast: Investors Prepare For Earnings Tsunami

via: SeekingAlpha at 2018-01-29 05:48:23:000

While stock index futures are down slightly to start the week, the market could continue its record-setting run with the S&P 500 already on track for a 7.2% gain in January. More than a fifth of the S&P 500 companies will release earnings this week, ranging from tech's he… read more...

Wall Street Breakfast: Investors Prepare For Earnings Tsunami

via: SeekingAlpha at 2018-01-29 05:48:23:000

While stock index futures are down slightly to start the week, the market could continue its record-setting run with the S&P 500 already on track for a 7.2% gain in January. More than a fifth of the S&P 500 companies will release earnings this week, ranging from tech's he… read more...

Ablynx: Will Novo Nordisk Up Its Bid?

via: SeekingAlpha at 2018-01-23 12:48:37:000

Ablynx ( ABLX ), a Belgium-based biopharmaceutical company has seen a lot of action in recent months. In October, the company reported positive results from a critical Phase 3 trial of Caplacizumab, a treatment for thrombotic thrombocytopenic purpura, or TTP, a rare blood disease . The posi… read more...

Bioverativ's Shareholders Hit The Jackpot

via: SeekingAlpha at 2018-01-23 12:23:27:000

Sanofi (NYSE: SNY ) has agreed to buy Bioverativ (NASDAQ: BIVV ) for $11.6 billion, or $105 per share in cash. Bioverativ is the Hemophilia-business unit that was spun-off from Biogen in 2017. In 2007 Biogen acquired Syntonix Pharmaceuticals and this take-over yielded two FDA approved Hemop… read more...

Stocks To Watch: Earnings Season Hits Higher Gear

via: SeekingAlpha at 2018-01-20 08:27:52:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...

Novo Nordisk: Don't Spoil The Ablynx Acquisition

via: SeekingAlpha at 2018-01-17 15:16:23:000

Novo Nordisk's bid on Ablynx On January 8, 2017, Novo Nordisk ( NVO ), the Danish multinational pharmaceutical giant, made a public announcement that it wanted to acquire the Belgian biotech company Ablynx ( ABLX ) ( ABLYF ). Novo Nordisk offered $33 per share, which means a total amount … read more...

Ablynx (ABLX) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-09 13:47:15:000

The following slide deck was published by Ablynx NV in conjunction with this Read more … read more...

Biotech Forum Daily Digest For Jan. 8th

via: SeekingAlpha at 2018-01-08 12:14:20:000

"There is no more disastrous mania, no more dangerous whim, than the speculation over roads not taken." - Juan Gabriel Vsquez, The Sound of Things Falling It was a good start for the markets in the first holiday shortened week of 2018. The Dow hit 25,000 for the first time ever and p… read more...

Novo bids $3.1B for Ablynx

via: SeekingAlpha at 2018-01-08 06:52:49:000

Novo Nordisk (NYSE: NVO ) has made a 2.6B ($3.1B) offer to acquire Ablynx ( OTCPK:ABLYF )(NASDAQ: ABLX ). Novo announced its 28 per share bid after the Belgian biotech rejected earlier approaches. Analysts believe Novo will have to sweeten its offer to close the deal. Jeffe… read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Ablynx (ABLX) Phase III HERCULES Study With Caplacizumab In Acquired Thrombotic Thrombocytopenic Purpura (aTTP) - Slideshow

via: SeekingAlpha at 2017-12-13 13:38:47:000

The following slide deck was published by Ablynx NV in conjunction with this Read more … read more...

Ablynx: To ASH And Beyond

via: SeekingAlpha at 2017-11-28 15:08:27:000

Shares of Belgium-based biotech firm Ablynx ( ABLX ) have shown signs of waking up since their October IPO. ABLX data by YCharts With a market capitalization of around $1.7 billion, the company is focused on developing their nanobodies derived from heavy-chain only antibodies. They bel… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX